𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia – results of a phase-II trial

✍ Scribed by F. Schneller; M. Schuler; K. Schumacher; J. Thaler; C. Peschel; C. Huber; W. Aulitzky

Book ID
105990406
Publisher
Springer
Year
1998
Tongue
English
Weight
68 KB
Volume
77
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of terminal-phase chronic myel
Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea
✍ Dr M. Lazzarino; E. Morra; E. Brusamolino; E. P. Alessandrino; E. Orlandi; G. Pa 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 505 KB

We used intermediate doses of Ara-C (IDAra-C) in the treatment of 15 patients with chronic myelogenous leukemia (CML) in blast crisis and, combined with hydroxyurea, in 20 CML patients in accelerated phase. Patients with blastic CML received intensive 5-day courses of IDAra-C 600 mg/m2 every 12 h as

A Phase I–II trial of escalating doses o
A Phase I–II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia
✍ Charles A. Koller; Hagop M. Kantarjian; Eric J. Feldman; Susan O'Brien; Mary Bet 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## BACKGROUND. Cytarabine is an essential drug for inducing remission of acute myelogenous leukemia, and it is also one the most effective drugs used as salvage therapy for patients with all types of relapsed acute leukemia. Nevertheless, there is considerable room for improvement in the treatment